Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5700772 | European Journal of Surgical Oncology (EJSO) | 2017 | 24 Pages |
Abstract
BIA-ALCL is a rare neoplasm with a good prognosis. Our data support the recommendation that stage I disease be managed with surgery alone. Adjuvant chemotherapy may be required for more invasive disease and our experience has shown the efficacy of Brentuximab as a second line treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
L. Johnson, J.M. O'Donoghue, N. McLean, P. Turton, A.A. Khan, S.D. Turner, A. Lennard, N. Collis, M. Butterworth, G. Gui, J. Bristol, J. Hurren, S. Smith, K. Grover, G. Spyrou, K. Krupa, I.A. Azmy, I.E. Young, F.A. MacNeill,